ADB-FUBIATA (AD-18, FUB-ACADB, ADB-FUBIACA) is a
synthetic cannabinoid compound first identified in 2021. It is closely related in structure to the older compound
ADB-FUBICA but with the
amide linker group extended by the addition of a
methylene bridge. It started to be sold as an ingedient in grey-market synthetic cannabis blends following the introduction of legislation in China which for the first time introduced
general controls on various classes of synthetic cannabinoids,[2] but did not encompass compounds where the linker group had been extended in this fashion. ADB-FUBIATA has many times lower affinity for
cannabinoid receptors than ADB-FUBICA with an EC50 of only 635 nM at CB1, but retains full agonist activity at this target, while being practically inactive at CB2.[3][4]
Legality
In the United States ADB-FUBIATA is unscheduled at the federal level as of May 22, 2023 but may be considered under the
federal analogue act if sold for human consumption. North Dakota has placed ADB-FUBIATA into Schedule I on 04/27/2023.[5]
^"关于将合成大麻素类物质和氟胺酮等18种物质列入《非药用类麻醉药品和精神药品管制品种增补目录》的公告" [Announcement on the inclusion of 18 substances including synthetic cannabinoids and fluamine in the "Additional Catalogue of Controlled Varieties of Non-medicinal Narcotics and Psychotropic Drugs"]. Ministry of Public Security of the People's Republic of China (in Chinese). 12 May 2021.